ArticleCureus2025
Impact of Saroglitazar on Liver Stiffness Measurements in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) With Compensated Cirrhosis: A Single-Arm Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Saroglitazar, a dual peroxisome proliferator-activated receptor α/γ agonist, shows promise in metabolic dysfunction-associated steatotic liver disease (MASLD). However, its impact and safety in MASLD with compensated cirrhosis (MASLD-CC) remain relatively unexplored. Methods In a single-center, single-arm retrospective study, we assessed the impact of Saroglitazar (4 mg for 24 weeks) on liver stiffness measurement (LSM) by magnetic resonance elastography (MRE) in MASLD-CC and evaluated safety and effects on biochemical indices and liver fat content (LFC) by MRI-proton density fat fraction (MRI-PDFF). To distinguish measurement error from true change, a threshold of 0.75 kPa for MRE-LSM was used to categorize LSM progressors and regressors. Results Twenty-six patients with MASLD-CC (age 61 (58-64) years; 61.5% female; BMI 28.7 ± 3.3 kg/m²; 88.4% obese; 76.9% with diabetes) completed 24 weeks of follow-up. Body weight (69.5 (64-75) vs 68.3 (66-71) kg, p = 0.02), alanine transaminase (42.5 (30-61) vs 22.5 (20-36) U/L), aspartate transaminase (53 (39-74) vs 40 (33-49) U/L), fasting blood sugar (109 (100-129.5) vs 100.5 (96.3-108.3) mg/dL), total cholesterol (157 (139.5-171) vs 140 (120-167) mg/dL), triglycerides (121 (95-153) vs 100 (94-113.5) mg/dL), and LFC (7.2 (6.9-11.1) vs 5.1 (3.5-6.1) %) decreased with Saroglitazar (p < 0.01 for all). A decrease in MRE-LSM (5.4 (4.9-6.2) vs 5.1 (4.9-5.8) kPa) was seen in the overall cohort (p = 0.04). However, only 4 (15.3%) and 2 (7.6%) showed MRE-LSM regression and progression of ≥ 0.75 kPa, respectively. No differences were noted between regressors and progressors using the 0.75 kPa threshold (23.5% vs 22.2%, p = 0.91). Two patients (pruritus and increased urine frequency) reported adverse events. Conclusion Saroglitazar use over 24 weeks in MASLD-CC appears safe. Using pragmatic thresholds, changes in liver stiffness over 24 weeks did not differ significantly. Larger prospective studies with longer follow-up are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.